Companies: 10,795·Total market cap: $144.5T
Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

CRLNYSEHealthcare● Active
$185.05
+$3.71(+2.05%)
Market Cap$8.9B
P/E Ratio
52W High$228.88
52W Low$140.78
Overview

Charles River Laboratories International, Inc. (CRL) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CRL · net income · updated Jun 8, 2026

Core profitability metrics

Net income was −$144.3M for FY2025 (fiscal year ending 2025-12-27), down 1501.7% year-over-year. Net profit margin was -3.6%. Based on available data, Charles River Laboratories International, Inc. has been profitable since at least 2011.

FY2025 Net Income−$144.3M▼ -1501.7% YoY
Trailing 12M (TTM)−$184.7Mtrailing 4 quarters sum
Net Profit Margin-3.6%−$144.3M ÷ $4.02B
YoY Change-1501.7%
5-Year CAGRN/AN/A — contains loss years
FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net IncomeNet LossNet Margin %★ First Profit: 2011

▸ FMP /income-statement · Annual · CRL net income history · CRL profit margin

Annual net income data

Fiscal YearNet IncomeYoY ChangeNet Margin
FY2025Loss−$144.3M▼ 1501.7%-3.6%
FY2024$10.3M▼ 97.8%0.3%
FY2023$474.6M▼ 2.4%11.5%
FY2022$486.2M▲ +24.4%12.2%
FY2021$391.0M▲ +7.3%11.0%

Net income vs peers (Healthcare)

#CompanyNet IncomeYoY
#1
Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.YOU
CRL
−$144.3M-1501.7%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$26.80B+90.6%
#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$20.64B+94.9%
#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$12.06B-16.3%
#5
AbbVie Inc.
AbbVie Inc.
ABBV
$4.23B-1.2%
Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Charles River Laboratories International, Inc. (CRL) reported net income of −$144.3M for FY2025 (fiscal year ending 2025-12-27), down 1501.7% year-over-year. The net profit margin was -3.6% — meaning the company kept $-0.04 of every dollar of revenue as profit.

Based on available data, Charles River Laboratories International, Inc. has been profitable since at least 2011. Net income reached a peak of $486.2M in FY2022. Data available for 15 fiscal years.

Charles River Laboratories International, Inc.'s net profit margin was -3.6% for FY2025, based on the latest annual results.

Investors sometimes search for "Charles River Laboratories International, Inc. net worth" — the company's market capitalization is a separate figure from CRL net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Frequently asked questions

CRL net income · 4 questions

Charles River Laboratories International, Inc. is not currently profitable on an annual basis. The company reported a net loss of $144.3M for FY2025.

is CRL profitabledoes CRL make a profitCRL profitabilityCRL profitable company

Source: FMP /income-statement · GAAP · Charles River Laboratories International, Inc. · Charles River Laboratories International, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026